Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis

Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis

Show other versions (1)

Current options for treating tuberculosis (TB) that is resistant to rifampicin (RR-TB) are few, and regimens are often long and poorly tolerated. Following recent evidence from the TB-PRACTECAL trial countries are considering programmatic uptake of 6-month, all-oral treatment regimens. We used a Mar...

Full description

Bibliographic Details
Main Authors: Sedona Sweeney, Catherine Berry, Emil Kazounis, Ilaria Motta, Anna Vassall, Matthew Dodd, Katherine Fielding, Bern-Thomas Nyang’wa
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-01-01
Series:PLOS Global Public Health
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022130/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022130/?tool=EBI

Similar Items